Table 1.
Characteristics of systematic reviews.
| Author, year | Electronic databases (year) | Number of studies included (number of study population) | Intervention (participants) | Comparison interventions (participants) | Course (d) | Main outcome | Types of participants | Quality assessment | Quality of primary studies |
|---|---|---|---|---|---|---|---|---|---|
| Hu et al., 2009 [13] | CNKI, Wanfang, VIP (1994–2008) |
12 (950) |
DHI + RT (477) |
CDI, XSTI, VI, BC + RT (473) |
14–21 d | ①② | AIS | Jadad | Poor |
|
| |||||||||
| Xu et al., 2010 [14] | CNKI, Wanfang, VIP, CBM (NA) |
9 (996) |
DHI | XDI, CXQI HI, RT, DI, CDI, XSTI | 14–30 d | ①② | AIS | Jadad | Poor |
|
| |||||||||
| Xiong et al., 2014 [15] | CBM, FMJS, CNKI, Wanfang, VIP, duxiu (2009–2014) |
21 (2725) |
DHI | NA | NA | ① | IS | Jadad | Poor |
|
| |||||||||
| Ye et al., 2010 [16] | CNKI, PubMed (2004–2009) |
45 (4027) |
DHI | CDI, RT, VI, XSTI, CXQI, and so forth | 7–30 d | ① | IS | Jadad | Poor |
|
| |||||||||
| Yang and Zeng, 2012 [17] | CNKI, Wanfang (2006–2010) |
27 (2583) |
DHI + RT | DSI, CDI + RT | NA | ①② | IS | Cochrane Handbook | B Grade |
|
| |||||||||
| Liu et al., 2014 [18] | CNKI, Wanfang (2004–2014) |
9 (885) |
DHI + RT | RT | 7–14 d | ① | AIS | Cochrane Handbook | B or C Grade |
|
| |||||||||
| Peng et al., 2010 [19] | Medline, Embase, CBM, CNKI, VIP, Wanfang (2000–2010) |
29 (3191) |
DHI | CDI | 14–30 d | ①②③ | AIS | Cochrane Handbook | B Grade |
|
| |||||||||
| Ma et al., 2012 [20] | CBM, VIP, Medline, Cochrane (up to 2011) |
14 (1112) |
DHI + RT | RT | 14–21 d | ①② | AIS | Jadad | Poor |
DHI, Danhong injection; RT, routine therapy; CDI, Compound Danshen Injection; XSTI, Xuesetong injection; VI, Venoruton injection; BC, black control; XDI, Xiangdan injection; CXQI, Chuanxiongqin injection; HI, hydroxyethyrutin injection; DI, Dextran injection; NA, not available; DSI, Danshen injection; AIS, acute ischemic stroke; IS, ischemic stroke; FMJS, foreign medical journal full-text service.
① Clinical efficiency; ② neurological deficits score; ③ deterioration and mortality.